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Abstract: Methotrexate (MTX) is an important component in the therapy used to treat childhood 
acute lymphoblastic leukemia (ALL). Methylenetetrahydrofolate reductase (MTHFR) is a key 
enzyme for MTX pharmacokinetics. Two single-nucleotide polymorphisms in MTHFR gene, 
C677T and A1298C, affecting MTHFR activity, have been widely studied as potential markers 
of MTX toxicity and/or outcome in pediatric ALL. In this review, we show that the majority of 
published reports do not find association or present opposite effect. Therefore, MTHFR C677T 
and A1298C polymorphisms do not seem to be good markers of MTX-related toxicity and/or 
outcome in pediatric ALL. The efforts should be focused on other genes, such as transporter 
genes or microRNA-related genes.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children, 
representing ~30% of all childhood malignancies.1,2 Survival rates have increased 
dramatically over the last years because of chemotherapy progress, with expected cure 
rates higher than 80%.3 Methotrexate (MTX) is an important drug used in the treatment 
protocols for ALL. However, MTX can cause toxicity, leading to a dose reduction or 
treatment interruption, which could compromise the survival.
MTX is a folate analog that enters the cell via active transport mediated by the 
reduced folate carrier (RFC1).4 Then, MTX inhibits dihydrofolate reductase, arrest-
ing the folic acid cycle and affecting other important enzymes such as methylene-
tetrahydrofolate reductase (MTHFR), an enzyme that interferes with nucleic acid 
synthesis and favors cell death.5 Thus, MTHFR is a key enzyme for intracellular 
folate homeostasis and metabolism, because it catalyzes the irreversible conversion 
of 5,10-methylenetetrahydrofolate, required for purine and thymidine synthesis, to 
5-methyltetrahydrofolate, required for protein synthesis and nucleic acid methylation. 
Subsequently, changes in the activity of MTHFR provoking an impaired conversion 
of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate could modify folate 
pools and in turn alter the response of malignant and nonmalignant cells to MTX and 
influence its toxicity6 (Figure 1).
In this context, two of the MTHFR polymorphisms most widely studied in relation to 
the toxicity of MTX are C677T (causing Ala222Val) and A1298C (causing Glu429Ala). 
Both polymorphisms have been associated with reduced enzyme activity. In the case 
of C677T, 677CT and 677TT individuals exhibit 60% and 30% of the normal MTHFR 
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activity, respectively.7,8 In the case of A1298C, 1298CC 
individuals show 60% of the normal activity.9 Therefore, 
the patients carrying the variant alleles might have a higher 
intolerance to MTX or an increased risk of progression.8
MTX intolerance can manifest through adverse reactions 
of several organ systems such as hematological (anemia, 
thrombocytopenia, leukopenia, neutropenia), gastrointestinal 
(mucositis), hepatobiliary, urogenital, or central nervous 
system.10 Also, MTX plasma levels are used as an objective 
MTX-related toxicity marker.11 In some patients, the toxic 
effects are so serious that the dose must be cut down or the 
treatment paused, which besides the problems related to 
toxicity, can also have a negative impact on survival.12
As we have mentioned herein, variants that alter MTHFR 
activity may increase the availability of 5,10-methylenetet-
rahydrofolate and decrease 5-methyltetrahydrofolate. The 
reduction of this last would lead to DNA hypomethylation, 
which could invoke carcinogenesis through three different 
mechanisms: chromosomal instability, reactivation of ele-
ments, and loss of imprinting.13 The loss of methylation might 
favor mitotic recombination, leading to loss of heterozygosity 
as well as promoting karyotypically detectable rearrange-
ments. Intragenomic parasitic DNA and other previously 
silent transposons may then be transcribed and even “jump” 
to other parts of the genome, leading to disruption of normal 
genes. Hypomethylation can likewise affect imprinted genes, 
which have been shown to contribute to carcinogenesis. 
Finally, genomic DNA hypomethylation can also increase 
through all the tumorigenic steps,14 from the benign pro-
liferations to the invasive cancers.13 Therefore, decreased 
MTHFR activity due to 677T or 1298C alleles could induce 
hypomethylation, and all these modifications can lead to an 
increase in carcinogenesis.
To date, several groups have investigated the potential 
role of MTHFR polymorphisms in relation to the toxic-
ity of MTX, as well as outcome in pediatric ALL, but the 
Figure 1 MTX pathway.
Note: MTX and its metabolites are indicated.
Abbreviations: ABCs, ABC family transporters; DHF, dihydrofolate; DHFR, dihydrofolate reductase; MTHFR, methylenetetrahydrofolate reductase; MTX, methotrexate; 
MTXPG, methotrexate polyglutamated forms; RFC1, reduced folate carrier; SHMT1, serine hydromethyl transferase; SLCs, SLC family transporters; THF, tetrahydrofolate; 
TS, thymidilate synthase; 5-CH-THF, 5-methyltetrahydrofolate; 5,10-CH2-THF, 5,10-methylenetetrahydrofolate.
ABCs
SLCs
MTXPG
Pyrimidine
synthesis
Double-Strand
breaks
dTMP
TS DHF
SHMT1
THF
DHFR
Enzyme
Transporter
Metabolites
Purine
synthesis
5,10-CH2-THF
dUMP
MTHFR
5-CH-THF
THF C677T
A1298C
Methionine
Protein synthesis
DNA methylation
Homocysteine
MTXPG
MTX
RFC1
MTX
 
Ph
ar
m
ac
og
en
om
ics
 a
nd
 P
er
so
na
liz
ed
 M
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
8.
22
7.
89
.3
3 
on
 1
6-
Ju
n-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Pharmacogenomics and Personalized Medicine 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
71
MTHFR SNPs in the MTX therapy of pediatric ALL
conclusions remain controversial. Some studies do not find 
association, whereas others present opposite effect. In con-
sequence, we consider that it would be interesting to clarify 
these discrepancies.
Toxicity and MTHFR C677T and 
A1298C polymorphisms
In 2013, our group performed an exhaustive search to identify 
studies that examined the association between the C677T 
and A1298C polymorphisms of MTHFR and MTX toxicity 
in pediatric ALL patients. We used the keywords and subject 
terms “MTHFR and acute leukemia”, and “MTHFR and 
polymorphism(s) and toxicity” to search PubMed (www.
ncbi.nlm.nih.gov/pubmed) for articles published through 
November 2011. We also carried out a meta-analysis with 
those articles supplying enough information on toxicity by 
genotype. The study was performed in a population composed 
only of pediatric ALL patients for short-term toxic effects 
including (MTX plasma levels, mucositis, hepatic toxicity, 
neutropenia, thrombocytopenia, anemia, and leucopenia).
The meta-analysis included 24 studies for C677T and 16 
studies for A1298C. For C677T, none of the analysis revealed 
a statistically significant association with toxicity. In the 
case of A1298C, only a slight protective effect of 1298CC 
genotype for leukopenia was observed.15 Therefore, we 
concluded that there was no evidence to support the use of 
either the MTHFR C677T or the A1298C single-nucleotide 
polymorphisms (SNPs) as MTX toxicity markers in pediatric 
ALL patients, and consequently the MTX dose should not 
be adjusted based on these variants.
At the same time, Yang et al16 performed another meta-
analysis studying the effect of C677T and A1298C MTHFR 
polymorphisms on MTX-induced myelosuppression, oral 
mucositis, liver, hematological, gastrointestinal, and neu-
rological toxicities. They only found a slight association 
between C677T and gastrointestinal toxicity in pediatric 
ALL. None of the polymorphisms was associated to any of 
the other studied toxicities, so again in this study, neither 
C667T nor A1298C were proved to be good toxicity markers 
for MTX dose reduction.
In spite of all this evidence, new studies are being pub-
lished every year analyzing the involvement of MTHFR 
C677T and A1298C polymorphisms in MTX toxicity in 
pediatric ALL treatment. Herein, we have performed an 
exhaustive search to identify new studies that explore the 
association between the C677T and A1298C polymorphisms 
of MTHFR and MTX-induced toxicity from November 2011 
to November 2016, following the same strategy as before.15 
Keywords “MTHFR” and “acute lymphoblastic leukemia” 
for PubMed database were used.
The search provided 186 records, 114 of them were 
directly discarded because they were published before 2011. 
From the remaining 72 papers, after abstract screening, 
50 were excluded for not analyzing C677T and A1298C 
 polymorphisms in pediatric ALL. For the other 22, full 
lecture was performed. Seven out of 22 articles were dis-
carded, 4 because they were not focused on the analysis 
of C677T and A1298C polymorphism and MTX-induced 
toxicities,17–20 and other 3 because they analyzed the effect 
of the C677T/A1298C haplotype in MTX-related toxicity 
and each genotype could not be evaluated separately.21–23 We 
finally reviewed 15 articles that analyzed the MTHFR poly-
morphisms in relation to MTX-induced toxicities in pediatric 
ALL patients. Of the 15 reviewed papers, 2 were discarded 
for analyzing only outcome, and 13 studies that analyzed 
the association with MTX induced toxicities remained. The 
search and study selection process are shown in Figure 2.
C677T polymorphism analysis
The 13 selected articles analyzed the C677T polymorphism in 
relation to MTX-induced toxicities. From them, only 5 found 
significant associations with toxicity, but with contradictory 
results: 2 studies related the T variant allele to a decrease in 
toxicity risk,24,25 whereas the other 3 associated it to increased 
risk (Table 1).26–28
When we analyzed those studies in depth, we again found 
discordant results (Table 2). The association study between 
MTX pharmacokinetics and C677T polymorphism showed 
that 7 out of 8 studies did not find significant association. 
Haase et al25 was the only study in which MTX levels were 
significantly increased in patients with the MTHFR C677T 
wild type compared to CT/TT genotype variant carriers. 
However, the number of patients included in this study was 
very low (n=35). In our previous meta-analysis, only one 
study found association, but the result was just the opposite.29 
Until now, taking into account our previous meta-analysis and 
the studies included in this review, a total of 13 studies have 
been performed about MTX pharmacokinetics, 11 with no 
association, and 2 with association but with opposite results. 
Therefore, C677T could not be considered as a good marker 
for MTX pharmacokinetics.
With regard to hematological toxicity, when anemia was 
analyzed, only 2 out of 5 studies found association. Haase 
et al25 showed that the variant of C677T was associated with a 
decreased toxicity, whereas Zgheib et al27 found the opposite 
effect. The other 3 studies found no association with anemia 
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(Table 2). Contradictory results were also seen for leukopenia, 
for which Haase et al25 showed that the C677T T variant allele 
was associated with a decreased toxicity, whereas Aráoz et al26 
found that this allele increased the risk of severe leukopenia, 
but only in carriers who received 2 g/ m2 of MTX. However, 
Aráoz et al26 also observed that the 677T allele did not seem 
to modulate the presence of severe adverse events in patients 
who received 5 g/m2 of MTX. The analysis of leukopenia in 
the other 3 studies showed no association with toxicity (Table 
2). Neutropenia was analyzed in 4 studies. Only the study of 
Aráoz et al26 found risk 677T allele associated to neutropenia 
in patients who received low doses of MTX (2 g/m2). None 
of the other 3 studies found association. Again, these results 
are in line with the results of our previous meta-analysis in 
which we proposed that C677T polymorphism does not seem 
to be a good marker for hematological toxicity.
Hepatotoxicity was analyzed in 7 studies, and only the 
study of Fukushima et al28 found significant association for 
677CT/TT carriers. This study was conducted in a cohort 
of 103 Japanese patients, that mixed ALL (n=82) and non- 
Hodgkin lymphoma (NHL) (N=21) patients. In contrast, 
another study carried out in another Japanese population 
found no significant association.30 The other 5 studies per-
formed in other populations found no significant association 
Figure 2 Flow diagram of study selection.
Abbreviation: MTX, methotrexate.
7 records excluded
No association study 
Full text records assessed for eligibility N=22
Full text articles included N=15
50 records excluded:
32 focused on susceptibility
4 carried out with adult patients
5 review / meta-analysis, no new data presented
2 case study
2 not in English
4 not MTX toxicity data
1 letter
Records published after 2011 N=72
13 toxicity studies
5 toxicity
8 toxicity and outcome
8 outcome studies
2 outcome
6 toxicity and outcome
7 records excluded
2 toxicity and outcome studies published before 2013
5 toxicity studies
2 records excluded
2 outcome studies
Table 1 List of 13 studies that analyzed association between the 
MTHFR C677T polymorphism and MTX toxicity in pediatric ALL, 
grouped according to the level of association between the SNP 
and MTX toxicity
MTHFR C677T
Patient 
population
MTX 
dose
Population Association 
with toxicity
Reference, year
21 ALLC High Indian NA Moulik et al,31 2016
106 ALLC
High Turkish
NA Yazıcıoğlu et al,32 
2016
56 ALL or 
Lymphoma A High Japanese
NA Tsujimoto et al,47 
2016
53 ALLA Low Japanese NA Suzuki et al,30 2015
91 ALLC High Chinese NA Wang et al,48 2014
499 ALLA High German NA Radtke et al,39 2013
18 ALLC High Brazilian NA de Deus et al,49 2012
100 ALLA ND Korean NA Kim et al,50 2012
109 ALLC
High Mexican
–T Ramírez-Pacheco 
et al,24 2016
35 ALLB High Caucasian –T Haase et al,25 2012
161 ALLC High Argentinian +T Aráoz et al,26 2015
127 ALLC High Lebanese +T Zgheib et al,27 2014
103 ALL and 
NHLA High Japanese
+T Fukushima et al,28 
2013
Notes: Type of sample: A, normal; B, tumor; C, unknown. High MTX dose =1.5–5 
g m–2; Low MTX dose =25 mg m–2.
Abbreviations: MTHFR, methylenetetrahydrofolate reductase; SNP, single-nucleotide 
polymorphism; MTX, methotrexate; ALL, acute lymphoblastic leukemia; NHL, non-
Hodgkin Lymphoma; ND, no data; NA, no association between SNP and toxicity; +T, 
SNP is associated with increased toxicity; –T, SNP is associated with decreased toxicity. 
 
Ph
ar
m
ac
og
en
om
ics
 a
nd
 P
er
so
na
liz
ed
 M
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
8.
22
7.
89
.3
3 
on
 1
6-
Ju
n-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Pharmacogenomics and Personalized Medicine 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
73
MTHFR SNPs in the MTX therapy of pediatric ALL
either. Once more, these results are in line with the results 
found by our group in the previous review, in which 13 studies 
out of 16 were not significant.
Mucositis was analyzed in 5 studies, and only Ramírez-
Pacheco et al24 concluded that CC genotype was associated 
with a higher risk of developing mucositis in a cohort of 
109 children with ALL. The rest of the 4 studies found no 
association, in line with our meta-analysis results in which 
8 out of 10 studies were not significant.
Finally, for thrombocytopenia and renal toxicity with 3 
studies and neurotoxicity with 2 studies, none of them found 
significant association. Once more, these results were in 
agreement with the previous ones.
In conclusion, after analyzing thoroughly a total of 37 
articles and 4,583 patients (24 studies with 3,104 patients 
from the previous meta-analysis and 13 studies with 1,479 
patients from our actual review) and considering that the 
majority of studies were not significant, the significant results 
were often contradictory or with low statistical power, we can 
conclude that C677T is not a good MTX toxicity marker in 
pediatric ALL.
A1298C polymorphism analysis
Of the 13 articles reviewed, 10 analyzed the association 
of A1298C polymorphism with MTX-induced toxicity 
(Table 3). From them, only 3 studies found significant asso-
ciation. Moulik et al31 and Haase et al25 showed the C variant 
allele favoring an increase in toxicity, whereas Fukushima 
et al28 showed a protective role for the C variant allele. When 
the different toxicities were considered, almost all the results 
found no significant associations (Table 4).
Regarding anemia, 3 of 5 studies found no significant 
results, whereas both Moulik et al31 and Haase et al25 found 
association with an increase in toxicity for patients carrying 
Table 2 Types of toxicities analyzed and the findings in each study of the association between the MTHFR C677T polymorphism and 
MTX toxicity
MTHFR C677T
Reference, 
year
MTX 
kinetics
Hematologic toxicity Hepatic 
toxicity
Mucositis Renal 
toxicity
Neurotoxicity Other
Anemia Thrombocytopenia Leukopenia Neutropenia
Moulik 
et al,31 2016
— NA NA — NA NA NA NA — NAa,b
Yazıcıoğlu 
et al,32 2016
NAc NA NA NA NA NA NA NA NA —
Tsujimoto 
et al,47 2016
— — — — — — — — NA —
Suzuki et al,30 
2015
— — — NA — NA — — — NAb
Wang et al,48 
2014
 NAd,e — — — — — — — — —
Radtke 
et al,39 2013
NAf,g,h — — — — — NA — — —
de Deus 
et al,49 2012
NAc — — — — NA — NA — —
Kim et al,50 
2012
— — — — — NA — — — NA b,i
Ramírez-
Pacheco 
et al,24 2016
NAc — — NA — — –T — — —
Haase et al,25 
2012
–Tc –T — –T — — — — — –Tj
Aráoz et al,26 
2015
— NA NA +T +T NA NA — — —
Zgheib 
et al,27 2014
 NAf, g,k +T — — NA — — — — NAb
Fukushima 
et al,28 2013
NAc — — — — +T — — — +Tl
Notes: Identifiers: afebrile neutropenia; bMTX dose reduction; cMTX levels; ddose corrected MTX level; epercent of MTX >40 mmol/L; fMTX clearance; gMTX AUC; hpeak 
MTX plasma level; isepsis;  jrate of cycles with infection; ktime to reach MTX level <0,1 mmol/L; lMTX administration delay; –, not evaluated. 
Abbreviations: MTHFR, methylenetetrahydrofolate reductase; SNP, single-nucleotide polymorphism; MTX, methotrexate; NA, no association between SNP and toxicity; 
+T, SNP is associated with increased toxicity; –T, SNP is associated with decreased toxicity.
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the CC genotype. These studies included a low number of 
patients (n=21 and n=35, respectively), whereas the studies 
that did not result in significance were performed in cohorts 
of 106,32 161,26 and 12727 patients. Since our previous review 
found no association in 5 of the 6 studies that analyzed ane-
mia and the one that showed association was performed in 
a population of 37 patients,33 we can conclude that A1298C 
variant is not a good marker for anemia.
Hepatotoxicity was analyzed in 7 studies, only Fukushima 
et al28 showed significant results in their cohort of children, 
which as previously mentioned, mixed 82 ALL patients and 
21 NHL patients. In this study, 1298CC genotype patients 
presented a lower hepatic toxicity risk comparing to the 
1298AA genotype patients. The other 6 studies did not find 
association between the polymorphism and hepatic toxicity. 
These results agree with our previous meta-analysis where 
8 out of 10 studies neither found significant association. 
Moreover, the 2 studies that showed association in the previ-
ous meta-analysis found the opposite effect for the variant C 
allele that increased hepatic toxicity.33,34
For MTX pharmacokinetics and A1298C since November 
2011, 6 new studies have been performed, but significant 
results have not been detected in any of them. These results in 
combination with the results from our previous meta-analysis, 
where only one study conducted in a population of 37 patients 
obtained significant results,33 give us a total confirmation of 
no association between the A1298C polymorphism and MTX 
pharmacokinetics.
None of the other analyzed toxicities (leukopenia, neutro-
penia, and mucositis with 4 studies; thrombocytopenia and 
renal toxicity with 3 studies; and neurotoxicity with 1 study) 
showed statistically significant results (Table 4).
The results from 26 articles and 3,546 patients (16 studies 
with 2,323 patients from the previous meta-analysis and 10 
studies with 1,223 patients from our actual review) makes 
us reject the MTHFR A1298C polymorphism as a MTX 
toxicity marker.
To sum up, in these 13 new studies analyzing C677T and 
A1298C and MTX-induced toxicities, we have confirmed our 
previous results. Most of the studies concluded that there was 
no association between MTHFR polymorphisms and MTX 
toxicity, and in those few studies with positive associations, 
opposite effects were often observed. Therefore, we consider 
that MTHFR C677T and A1298C polymorphisms are not 
good toxicity markers in pediatric ALL, and we think that 
no further studies are needed in this line.
Outcome and MTHFR C677T and 
A1298C polymorphisms
In 2014, He et al35 published the results of a meta-analysis 
that studied the relationship between the MTHFR C677T and 
A1298C polymorphisms and ALL relapse risk. They conducted 
a literature search of PubMed (www.ncbi.nlm.nih.gov/pubmed) 
and Web of Knowledge (http://isiknowledge.com/) using the 
following keywords and subject terms: “acute lymphoblastic 
leukemia and relapse and polymorphism (variant)” and “methy-
lenetetrahydrofolate reductase (MTHFR) and acute lympho-
blastic leukemia and relapse”, last updated on September 2013. 
The association between the two SNPs and ALL relapse was 
evaluated in childhood ALL patients. In He et al’s35 work, the 
meta-analysis for childhood ALL was performed with 6 studies 
for C677T (n=1,553) and with 3 studies for A1298C (n=711). 
Significant association was only found for C677T. According 
to their results, the relapse risk in pediatric ALL was higher for 
the 677TT genotype than for the CT/CC genotypes.
Simultaneously, Ojha and Gurney36 published a sys-
tematic review on the association between MTHFR C677T 
and overall survival in pediatric ALL (n=909). The search 
included literature through March 2013, and the review 
was based on 6 studies, 3 of them already included on He 
et al’ s,35 meta-analysis. As expected, they reached a similar 
conclusion, individuals with MTHFR 677T variant showed a 
higher relative risk of pediatric ALL mortality, with greater 
statistical support for the genotype MTHFR 677TT.
Herein, we performed a new review of the literature 
published after the mentioned two reviews, from September 
2013 to November 2016, to assess the relationship between 
Table 3 List of 10 studies that analyzed association between the 
MTHFR A1298C polymorphism and MTX toxicity in pediatric 
ALL, grouped according to the level of association between the 
SNP and MTX toxicity
MTHFR A1298C
Patient 
population
MTX 
dose
Population Association 
with toxicity
Reference, year
106 ALLC High Turkish NA Yazıcıoğlu et al,32 
2016
53 ALLA Low Japanese NA Suzuki et al,30 2015
161 ALLC High Argentinian NA Aráoz et al,26 2015
127 ALLC High Lebanese NA Zgheib et al,27 2014
499 ALLA High German NA Radtke et al,39 2013
18 ALLC High Brazilian NA de Deus et al,49 2012
100 ALLA ND Korean NA Kim et al,50 2012
103 ALL and 
NHLA
High Japanese –T Fukushima et al,28 
2013
21 ALLC High Indian +T Moulik et al,31 2016
35 ALLB High Caucasian +T Haase et al,25 2012
Notes: Type of sample: A, normal; B, tumor; C unknown. High MTX dose =1.5–5 g 
m–2; Low MTX dose =25 mg m–2.
Abbreviations: MTHFR, methylenetetrahydrofolate reductase; SNP, single-nucleotide 
polymorphism; MTX, methotrexate; ALL, acute lymphoblastic leukemia; NHL, non-
Hodgkin Lymphoma; ND, no data; NA, no association between SNP and toxicity; +T, 
SNP is associated with increased toxicity; –T, SNP is associated with decreased toxicity. 
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childhood ALL outcome and MTHFR C677T and A1298C 
polymorphisms. Keywords “MTHFR” and “acute lympho-
blastic leukemia” for PubMed database were used.
The study selection process, previously described for 
toxicity studies, was the same for outcome in the first steps. 
Out of the 15 articles selected for complete lecture, 7 were 
discarded, 2 for being published before 2013 and 5 for not 
studying outcome. Finally, we analyzed 8 articles that studied 
the MTHFR polymorphisms in relation to pediatric ALL 
patients outcome (Figure 2).
C677T polymorphism analysis
From 2013, eight studies that included 1,353 pediatric ALL 
patients have analyzed the association between the C677T 
polymorphism and outcome (relapse, death, or secondary 
malignancy). None of the new eight studies showed sig-
nificant association between outcome and C677T variant 
(Table 5). These results differ from the previously mentioned 
reviews that found association between increased relapse/
mortality risk and 677TT genotype. Nevertheless, in the He 
et al’s,35 meta-analysis, the significant result is based only in 
two studies (D’Angelo et al37 and Tantawy et al38) from the 
6 studies included. Taking all these results in consideration, 
we cannot affirm that MTHFR C677T polymorphism is a 
good outcome marker for pediatric ALL.
A1298C polymorphism analysis
In the case of A1298C, six new studies that included 1,104 
pediatric ALL patients analyzed the association with outcome 
(relapse, death, or secondary malignancy). From them, 2 
studies showed significant results but with opposite effect. 
Fukushima et al28 demonstrated that individuals with AC-CC 
genotypes presented increased Event Free Survival (EFS) 
(versus AA genotype), whereas Radtke et al’s39 study found 
that individuals with AC or CC genotypes showed decreased 
EFS (versus AA genotype) (Table 6). The other 4 studies 
showed no association between A1298C and outcome, which 
is in line with the previously published meta-analysis of He 
et al35 and other 3 studies. All these results together suggest 
that MTHFR A1298C polymorphism is not a good predictor 
for outcome in childhood ALL.
In conclusion, our review indicates that MTHFR C677T 
and A1298C polymorphisms cannot be considered as out-
come markers for childhood ALL.
Conclusion
Numerous studies have been performed analyzing the rela-
tionship between the C677T and A1298C polymorphisms 
of MTHFR and MTX toxicity and/or outcome in pediatric 
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ALL. The majority of these studies does not find association 
or present opposite effect. As a result, MTHFR C677T and 
A1298C polymorphisms cannot be considered as toxicity or 
outcome markers for childhood ALL. Therefore, the efforts 
should be focused on other genes. For instance, interesting 
and robust results have been obtained in regards to transporter 
genes and MTX toxicity. In fact, Treviño et al40 performed 
a genome-wide association study in patients with ALL and 
found rs4149081 and rs11045879 in SLCO1B1 strongly 
associated for the first time with MTX clearance, and this 
association was widely confirmed by subsequent studies.11,39,41 
As a result, other works have focused their interest on the 
analysis of polymorphism in MTX transporters, finding 
several SNPs in genes such as SLC19A1, ABCC4, or ABCC2 
also associated with MTX levels and other toxicities.42–44
Additionally, miRNA-related SNPs interfering with 
miRNA levels or function may lead to drug resistance/
sensitivity. Since miRNA expression can be exogenously 
controlled by blocking the expression of upregulated miRNAs 
or by restoring the expression of downregulated miRNAs, 
this field seems very promising in pharmacogenetics. Indeed, 
our group has detected 3 SNPs in miR-5189, miR-595, and 
miR-453 that might affect SLC46A1, SLC19A1, SLCO1A2, 
and ABCC4 MTX transport genes regulation and could affect 
MTX levels in patients with pediatric B-ALL.45,46
Disclosure
The authors report no conflicts of interest in this work.
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